The somatostatin analogue octreotide impairs sleep and decreases EEG sigma power in young male subjects.
The long-acting somatostatin (SRIF) analogue octreotide decreased nonrapid eye movement sleep (NREMS) in the rat. This effect is opposite to the promotion of sleep after growth hormone (GH)-releasing hormone (GHRH) in various species including humans. Therefore, it appears likely that GHRH and SRIF, besides their opposite action on pituitary GH release, interact reciprocally in sleep regulation. In previous studies, SRIF impaired sleep in elderly subjects, although sleep in young men remained unchanged. We hypothesized that octreotide is a useful tool to study the role of SRIF in human sleep regulation. We examined the effect of subcutaneous administration of 0.1 mg octreotide at 2245 on the sleep EEG of seven young male controls (age, mean+/-SD, 22.3+/-3.0 years). In comparison to placebo, octreotide administration prompted decreases of sleep stage 4 during the total night and of rapid eye movement sleep (REMS) density during the first half of the night. Intermittent wakefulness increased during the second half of the night. The spectral analysis of total night NREMS revealed a significant decrease of sigma power. Similar to the effect of the short-acting SRIF in the elderly, the long-acting SRIF analogue octreotide impaired sleep in young healthy subjects. Obviously, the influence of octreotide on sleep is superior to that of short-acting SRIF, which did not affect sleep in young men. We suggest a reciprocal interaction of GHRH and SRIF in sleep regulation.
Ziegenbein
M
M
Department of Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany.
Held
K
K
Kuenzel
H E
HE
Murck
H
H
Antonijevic
I A
IA
Steiger
A
A
D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D004569:Electroencephalography / Q000187:drug effects*; D006801:Humans; D008297:Male; D015282:Octreotide / Q000009:adverse effects / Q000494:pharmacology*; D012894:Sleep Stages / Q000187:drug effects; D012893:Sleep Wake Disorders / Q000139:chemically induced*; D013004:Somatostatin / Q000031:analogs & derivatives; D013997:Time Factors
D013004:Somatostatin; D015282:Octreotide